Scholarlink

Aim of the Study <p>This study aims to investigate the anticancer potential of <i>Sarcostemma acidum</i> extract (SAE) against the Ehrlich ascites carcinoma (EAC) using a network pharmacology-guided approach, along with in-vitro and in-vivo evaluation.</p> Materials and Methods <p>SAE was prepared using hydroalcoholic extraction (1:4 ratio) and analyzed by GC-MS to identify bioactive compounds. The biological targets were identified subsequently through SuperPred in relation to EAC genes from GeneCards. Further, it is complemented by protein-protein interaction, Gene Ontology, and KEGG analyses, alongside molecular docking studies. Cytotoxicity was tested in-vitro, and in-vivo efficacy was evaluated in Swiss albino mice across five groups by measuring tumour growth and hematological parameters.</p> Results <p>GC-MS analysis identified key compounds including methyl linoleate and pseudosarsasapogenin-5,20-dien methyl ether, while network pharmacology revealed 12 shared genes between SAE-derived compounds and EAC, notably highlighting PTGS2, MAPK1, and PIK3CA as primary targets. Docking studies demonstrated significant binding affinities for pseudosarsasapogenin, and in-vitro and in-vivo investigations showed that SAE effectively reduced tumour metrics and improved hematological parameters at a dosage comparable to established therapies.</p> Conclusion <p>The <i>Sarcostemma acidum</i> extract demonstrated marked antitumor activity against EAC, likely through modulating essential oncogenic pathways, notably TNF signalling.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Unraveling the Antitumor Potential of Sarcostemma acidum Against Ehrlich Ascites Carcinoma: Integrating Network Pharmacology with Experimental Approach

  • 期刊论文

  • 发表日期：

    2026年3月10日

查看全文
  • Abhishek Digar,
  • Sourav Ghosh,
  • Monosiz Rahaman,
  • Biswajit Basu,
  • Bhupendra Prajapati

摘要

Aim of the Study

This study aims to investigate the anticancer potential of Sarcostemma acidum extract (SAE) against the Ehrlich ascites carcinoma (EAC) using a network pharmacology-guided approach, along with in-vitro and in-vivo evaluation.

Materials and Methods

SAE was prepared using hydroalcoholic extraction (1:4 ratio) and analyzed by GC-MS to identify bioactive compounds. The biological targets were identified subsequently through SuperPred in relation to EAC genes from GeneCards. Further, it is complemented by protein-protein interaction, Gene Ontology, and KEGG analyses, alongside molecular docking studies. Cytotoxicity was tested in-vitro, and in-vivo efficacy was evaluated in Swiss albino mice across five groups by measuring tumour growth and hematological parameters.

Results

GC-MS analysis identified key compounds including methyl linoleate and pseudosarsasapogenin-5,20-dien methyl ether, while network pharmacology revealed 12 shared genes between SAE-derived compounds and EAC, notably highlighting PTGS2, MAPK1, and PIK3CA as primary targets. Docking studies demonstrated significant binding affinities for pseudosarsasapogenin, and in-vitro and in-vivo investigations showed that SAE effectively reduced tumour metrics and improved hematological parameters at a dosage comparable to established therapies.

Conclusion

The Sarcostemma acidum extract demonstrated marked antitumor activity against EAC, likely through modulating essential oncogenic pathways, notably TNF signalling.

Graphical Abstract